Fresenius Kabi opens €15M biosimilar R&D center in Eysins, Switzerland

Fresenius Kabi SwissBioSim opened a new R&D center for biosimilars in Eysins, Switzerland, with an investment of about €15 million. The center will focus on autoimmune diseases and oncology, and currently employs over 100 people.

“Fresenius Kabi SwissBioSim, a Fresenius Kabi company, opened a new research and development center for biosimilars in Eysins, Switzerland.”bioalps.org

• 1 source
• bioalps.orgFresenius Kabi expands biosimilar research activities in Eysins - BioAlpsMagali BischofSep 18, 2019

Summarized from public sources; check the original articles before acting on it.